Thermo Fisher deploys $8.9B for Clario acquisition, lifts buybacks to $3B amid tariff headwinds

Filed May 1, 2026 · Period ending March 28, 2026 · Compared to 10-Q May 2, 2025 · ~2 min read

Key Changes

• high

  Completed $8.9B acquisition of Clario Holdings on March 24, 2026, adding endpoint data solutions for clinical trials and expanding patient data analytics capabilities in the Laboratory Products and Biopharma Services segment.

  MD&A: Clario acquisition verify on EDGAR →
• high

  Total debt increased $9B to $43.2B to fund Clario acquisition, $3B in share repurchases (up from $2B prior year), and dividends; cash declined $6.6B to $3B as company deployed capital aggressively.

  MD&A: Capital deployment verify on EDGAR →
• high

  Revenue grew 6% to $11.0B driven by acquisitions (3 pts) and currency (2 pts); organic growth held at 1% as pharma/biotech demand strengthened but electron microscopy reversed from $80M growth to $27M decline.

  MD&A: Revenue growth verify on EDGAR →